Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsOscar Health HER2 Drug Prior Auth Coverage | OpenP…
    Ask Trek AI about this page
    CurrentOscar HealthPolicy CG101

    Antineoplastics - HER2-Targeted Agents - Medical Benefit Preferred Physician-Administered Drug Exceptions Criteria

    Customize your policy alerts

    Sign up for Oscar Health Policy CG101 alerts

    Get alerted when Policy CG101 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and medical-benefit exception criteria for non-preferred, non-trastuzumab HER2-targeted antineoplastic monoclonal antibodies.

    Policy Summary
    PayerOscar Health
    PolicyAntineoplastics - HER2-Targeted Agents - Medical Benefit Preferred Physician-Administered Drug Exceptions Criteria
    Policy CodePolicy CG101
    Change TypeNo material change
    Effective DateN/A
    Last ReviewMar 2, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with clinical documentation supporting the non-preferred product exception request.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4Preferred HER2-targeted products
    1Non-preferred HER2-targeted product
    2

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Preferred products requiring treatment failure
    12 monthsMaximum authorization period
    3 monthsInitial transition or shortage authorization
    5Applicable billing codes

    Coverage Criteria

    Experimental, Investigational, or Not Medically Necessary Use

    Non-preferred products are not covered for experimental, investigational, or medically unnecessary indications.

    Experimental, investigational, or not medically necessary use: The requested use is outside FDA-approved labeling or is not supported by current medical evidence and standards of care; is not clinically appropriate based on indication, age, dosing, duration, frequency, site of administration, or contraindication; is an inadequately supported off-label use; exceeds FDA-approved dosing or clinical practice guidelines without sufficient evidence supporting safety and efficacy; is not required to treat or manage the member's medical condition; is not aligned with generally accepted medical practice; or is primarily for the convenience of the member, family, or provider.

    Any listed condition may support non-coverage.

    This policy applies only to non-trastuzumab HER2-targeted agents. Trastuzumab products and their biosimilars—including Herceptin, Kanjinti, and Trazimera—are outside the scope of this policy and should be reviewed under CG082.

    The current-treatment transition exception does not apply when the requested product was obtained as samples or through an assistance program.

    Use of a non-preferred product is not medically necessary when it is not required to treat or manage the member’s condition, is not aligned with generally accepted medical practice, or is used primarily for the convenience of the member, family, or provider.

    Use is not medically necessary when the indication is outside FDA-approved labeling or is not supported by current medical evidence and standards of care, including inadequately supported off-label use or dosing that exceeds the FDA-approved label or clinical practice guidelines without sufficient evidence of safety and efficacy.

    Coding and Authorization Parameters

    CPT/HCPCS Codes considered medically necessary if criteria are metHCPCSCovered
    J9306Injection, pertuzumab, 1 mg
    J9316Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg
    J9353Injection, margetuximab-cmkb, 5 mg
    J9354Injection, ado-trastuzumab emtansine, 1 mg
    J9358Injection, fam-trastuzumab deruxtecan-nxki, 1 mg
    Preferred-product treatment failure
    RequirementInadequate response or treatment failure with at least TWO preferred products.
    Exception pathwayTreatment failure is one qualifying pathway for coverage of a non-preferred product.
    Authorization conditionClinical documentation must support the exception request in addition to the treatment-failure criterion.
    Standard exception authorization
    Authorization durationUp to 12 months when the prior authorization criteria are met.
    EligibilityThe member must meet one qualifying exception criterion for the non-preferred product.

    Provider Submission Requirements

    Prior Authorization

    Submit a Preferred-Drug Exception Request

    Submit a Medical Benefit Preferred Drug Exceptions request for a non-preferred product through the applicable review entity and submission channel. Oncology requests are reviewed by EviCore through the provider portal at www.evicore.com or by phone at 855-252-1118; non-oncology requests are submitted to Oscar by fax at 800-540-2406 or through provider.hioscar.com, including the form available at www.hioscar.com/forms. Check requirements or request status at provider.hioscar.com or 1-855-672-2755.

    • The program applies to members requesting treatment with a non-preferred product.
    • If approved, authorization may be provided for up to 12 months.
    • State mandates may apply.
    Step Therapy

    Preferred Products Must Generally Be Tried First

    Preferred products generally must be tried first when the provider considers them safe and effective. Request an exception only when the member has tried and failed, cannot use, or is otherwise eligible to bypass all applicable preferred products.

    Policy Background

    This policy addresses physician-administered antineoplastic monoclonal antibodies targeting HER2/neu under the medical benefit. Oscar maintains a preferred drug list to encourage clinically appropriate and cost-effective specialty-drug use, while allowing prior-authorization exceptions for non-preferred products when the policy’s clinical requirements are met. The policy covers non-trastuzumab HER2-targeted agents; trastuzumab products and biosimilars are addressed separately under CG082.

    Definitions

    Compendia
    DefinitionSummaries of drug information and medical evidence used to support decision-making about the appropriate use of drugs and medical procedures.
    ExamplesExamples include AHFS Drug Information, Elsevier Clinical Pharmacology, the NCCN Drugs and Biologics Compendium, Thomson Micromedex DrugDex, and USP-NF.
    UseCompendia support decisions about appropriate drug and medical-procedure use.
    Contraindication
    DefinitionA pre-existing condition or factor that precludes use of a drug because of risk of harm.
    Exception standardA contraindication to preferred products may support an exception when it would not exist or be reasonably expected with the requested non-preferred product.

    Initial Therapy Criteria

    Initial Non-preferred Product Exception

    Coverage for a non-preferred product requires BOTH one qualifying exception pathway and supporting clinical documentation.

    Initial non-preferred product exception

    • Qualifying exception pathway

      • Failure of preferred products: Inadequate response or treatment failure with at least TWO preferred products.At least 2 preferred products
      • Intolerance: The member experienced documented intolerable adverse events to preferred products that preclude their continued use.
      • Contraindication:

    Continuation and Transition Criteria

    Drug Transition

    Continuation or transition coverage may be available when the member is currently receiving the requested product and coverage is required to complete the current course of treatment.

    Current treatment transition: The member is currently receiving treatment with the requested product, the product was not obtained as samples or through an assistance program, and coverage is required to complete the current course of treatment.

    Initial approval is up to 3 months or another duration supported by provider clinical rationale.

    Shortage or Unavailability Continuation

    Shortage or unavailability approvals may be extended when continued documentation supports the exception.

    Continued shortage or unavailability: The shortage or unavailability of preferred products continues and is documented.

    Initial approval is up to 3 months. If the shortage or unavailability resolves before the authorization period ends, the Plan may require transition to the preferred product at the next authorization period.

    Preferred-Product Step Therapy

    StepRequirementException pathways
    1Try preferred products first when safe and effective.A non-preferred product may be requested when the member has inadequate response or treatment failure with at least two preferred products; documented intolerable adverse events; a qualifying contraindication; shortage or unavailability of all preferred products; current treatment-transition circumstances; clinical evidence or guidelines favoring the requested product over all preferred products; or the request is for cancer treatment in a state prohibiting prerequisite trials.

    Authorization Duration Limits

    Non-preferred requested product
    Authorization durationUp to 12 months per authorization period.
    EligibilityThe member must meet one qualifying exception pathway for the non-preferred product.
    Supporting requirementClinical documentation must support the applicable exception request.
    Non-preferred requested product for drug transition
    Initial authorizationUp to 3 months.
    Alternative durationAnother duration may be authorized based on provider clinical rationale.
    Transition condition

    Trastuzumab Scope Note

    Billing Rule

    Refer trastuzumab products to CG082

    Trastuzumab products and their biosimilars are outside this policy. Address products such as Herceptin, Kanjinti, and Trazimera under CG082.

    • This policy applies to non-trastuzumab HER2-targeted agents only.
    Policy Summary
    PayerOscar Health
    PolicyAntineoplastics - HER2-Targeted Agents - Medical Benefit Preferred Physician-Administered Drug Exceptions Criteria
    Policy CodePolicy CG101
    Change TypeNo material change
    Effective DateN/A
    Last ReviewMar 2, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with clinical documentation supporting the non-preferred product exception request.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Authorization ParametersProvider Submission RequirementsPolicy BackgroundDefinitionsInitial Therapy CriteriaContinuation and Transition CriteriaPreferred-Product Step TherapyAuthorization Duration LimitsTrastuzumab Scope Note
    DocumentationClinical documentation must support the exception request.
    Drug transition initial approval
    Initial approvalUp to 3 months.
    Alternative durationAnother duration may be authorized based on provider clinical rationale.
    ApplicabilityApplies when the member is currently receiving the requested product and coverage is required to complete the current course of treatment.
    Drug shortage or unavailability initial approval
    Initial approvalUp to 3 months.
    Exception basisAll preferred products must be affected by drug shortage or unavailability.
    ExtensionApproval may be extended based on continued documentation of the shortage or unavailability.
    • A qualifying pathway may include inadequate response or treatment failure with at least two preferred products.
    • Other pathways include documented intolerable adverse events, a qualifying contraindication, shortage or unavailability of all preferred products, continuation of an existing treatment course, evidence or guidelines supporting preferential use of the requested product, or a state rule prohibiting prerequisite trials.
    • Coverage criteria require the member to meet one exception pathway and provide supporting clinical documentation.
    Documentation Required

    Provide Supporting Clinical Documentation

    Include clinical documentation supporting both the requested therapy and the claimed exception. Documentation should be current and sufficiently specific to establish the diagnosis, prior treatment history, and why all preferred products cannot be used.

    • Up-to-date chart notes, relevant test results, and relevant imaging reports supporting the diagnosis and treatment request.
    • Prescription claims records and/or prescription receipts documenting prior trials of alternatives.
    • Specific details of inadequate response or treatment failure; the nature and severity of adverse events; specific contraindications; the reasons all preferred products cannot be used; and notification of drug shortage or unavailability.
    • For intolerance, describe the specific intolerable effects and their impact on treatment, adherence, quality of life, or overall health.
    Denial Risk

    Exception Criteria and Documentation Are Required

    A non-preferred product may be denied when the member does not satisfy at least one qualifying exception pathway or when the clinical documentation does not support the requested exception. The request must establish why the preferred products cannot be used under the applicable criteria.

    • Documented failure or inadequate response to at least two preferred products, qualifying adverse events, a qualifying contraindication, shortage or unavailability of all preferred products, continuation of an existing course, guideline-supported preferential use, or an applicable state-mandated exception is required.
    • A contraindication must be specific to the preferred products and would not exist or be reasonably expected to occur with the requested product.
    • Continuation-of-treatment exceptions do not apply when the requested product was obtained as samples or through an assistance program.
    • Missing, vague, or insufficient chart notes, test results, imaging, prescription records, or exception-specific rationale creates denial risk.
    Denial Risk

    Unapproved or Non-Medically Necessary Use

    Do not request or use a non-preferred product for an experimental, investigational, or medically unnecessary indication. Such use is excluded when it is outside FDA-approved labeling or unsupported by current medical evidence and standards of care.

    • Off-label or non-FDA-approved use without sufficient evidence supporting safety and efficacy.
    • Doses exceeding FDA-approved labeling or clinical practice guidelines, including excessive dosage, frequency, duration, or an inappropriate site of administration, without sufficient supporting evidence.
    • Use that is not required to treat or manage the member's medical condition or is not aligned with generally accepted medical practice.
    • Use primarily for the convenience of the member, family, or provider.
    • Use that is clinically inappropriate based on the indication, age, dosing, duration, site of administration, or contraindications may be denied.
    DocumentationSpecific contraindications should be documented in the exception request.
    Intolerance
    DefinitionThe inability to tolerate or endure a medication or treatment because of difficult or harmful side effects, reactions, or hypersensitivities.
    Treatment impactThe effects negatively impact quality of life, ability to adhere, or overall health.
    DocumentationDocumentation should detail the specific intolerable effects and their impact on treatment.
    Documentation
    DefinitionWritten information supporting diagnoses and prior trials of alternatives.
    Clinical recordsExamples include up-to-date chart notes, relevant test results, and relevant imaging reports.
    Medication recordsPrescription claims records or prescription receipts may support prior trials of alternatives.
    Experimental or Investigational
    DefinitionProcedures, drugs, or devices that have not been proven effective or have not been approved by the appropriate regulatory bodies.
    Coverage implicationNon-preferred products are not covered for experimental or investigational indications.
    Medical-necessity reviewUse outside FDA-approved labeling or without support from current medical evidence and standards of care may be considered non-medically necessary.
    Medical Benefit Preferred Drug Exceptions Criteria
    DefinitionPlan requirements that must be met for a non-preferred drug to be approved for coverage.
    Preferred-drug trialsRequirements may include trying and failing preferred drugs first.
    Exception approvalApproval requires one qualifying exception pathway and clinical documentation supporting the request.
    The member has a contraindication to preferred products that would NOT exist or be reasonably expected to occur with the requested non-preferred product.
  1. Unavailability: There is a drug shortage or unavailability of ALL preferred products.All preferred products
  2. Evidence or guideline preference: Clinical evidence and/or current treatment guidelines, such as NCCN, support preferential use of the requested product over ALL preferred products.All preferred products
  3. State-specific cancer-treatment exception: The request is for cancer treatment in a state prohibiting prerequisite trials under applicable regulations.

    State mandates may apply.

  4. Supporting clinical documentation: Clinical documentation supports the applicable exception reason, including details of treatment failure, adverse events, contraindications, reasons all preferred products cannot be used, or shortage or unavailability.
  5. The member must be currently receiving the requested product and require coverage to complete the current course of treatment.
    Non-preferred requested product for shortage or unavailability
    Initial authorizationUp to 3 months initially.
    ExtensionThe authorization may be extended with continued documentation of the shortage or unavailability.
    Resolution of shortageIf the shortage or unavailability resolves before the authorization period ends, transition to the preferred product may be required at the next authorization period.